Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Pharma-Bio Serv (PBSV) over the last 17 years, with Q4 2025 value amounting to $15817.0.

  • Pharma-Bio Serv's Depreciation & Amortization (CF) rose 16681.85% to $15817.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $59866.0, marking a year-over-year increase of 15681.44%. This contributed to the annual value of $59866.0 for FY2025, which is 15681.44% up from last year.
  • Per Pharma-Bio Serv's latest filing, its Depreciation & Amortization (CF) stood at $15817.0 for Q4 2025, which was up 16681.85% from $15744.0 recorded in Q3 2025.
  • Over the past 5 years, Pharma-Bio Serv's Depreciation & Amortization (CF) peaked at $21424.0 during Q1 2021, and registered a low of $4589.0 during Q3 2024.
  • Its 5-year average for Depreciation & Amortization (CF) is $12754.9, with a median of $13064.5 in 2022.
  • As far as peak fluctuations go, Pharma-Bio Serv's Depreciation & Amortization (CF) plummeted by 5974.56% in 2024, and later soared by 24308.13% in 2025.
  • Quarter analysis of 5 years shows Pharma-Bio Serv's Depreciation & Amortization (CF) stood at $14290.0 in 2021, then fell by 10.43% to $12800.0 in 2022, then crashed by 42.25% to $7392.0 in 2023, then decreased by 19.81% to $5928.0 in 2024, then surged by 166.82% to $15817.0 in 2025.
  • Its last three reported values are $15817.0 in Q4 2025, $15744.0 for Q3 2025, and $18866.0 during Q2 2025.